AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
PharmaCyte Biotech Inc (NASDAQ:PMCB)
0.7266 USD
-0.025 3.275%Sponsored Reports
Loading...
| Previous Close (in USD) | 0.7512 |
|---|---|
| Change | -0.025 3.275% |
| 52 W H/L (in USD) | 3.230/1.920 |
| EBITDA (in USD) | -- |
| PE Ratio | -- |
| Volume | 86326 |
| Diluted Eps TTM | -1.48 |
| Total Assets (in USD) | 73.277M |
|---|---|
| Total Liabilities (in USD) | 0.587M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 68.04M |
| Market Cap (in USD) | 17.752 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Employees: 2
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Carlos A. Trujillo CPA, CPA | Chief Financial Officer | 1958 |
| 2. | Mr. Joshua N. Silverman | Interim CEO, Interim Pres & Interim Chairman | 1970 |
| 3. | Dr. Jose L. Iglesias M.D. | Consulting Chief Medical Officer | 1957 |
| 4. | Dr. Hans-Peter Hammes | Member of Medical & Scientific Advisory Board and Consultant | NA |
| 5. | Mr. Joshua N. Silverman | Interim CEO, President & Director | 1970 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.380 0.886% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 30-04-2023 | 30-04-2022 | 30-04-2021 | 30-04-2020 | 30-04-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -4.316M | -4.239M | -3.551M | -3.827M | -4.067M |
| Minority Interest | - | - | - | - | - |
| Net Income | -4.316M | -4.086M | -3.554M | -3.827M | -4.067M |
| Selling General Administrative | 5.987M | 3.701M | 2.707M | 3.525M | 3.641M |
| Gross Profit | - | - | - | - | - |
| Reconciled Depreciation | - | - | - | - | - |
| Ebit | -6.455M | -4.392M | -3.623M | -3.826M | -4.101M |
| Ebitda | -4.316M | -4.239M | -3.624M | -3.826M | -4.101M |
| Depreciation And Amortization | 2.14M | 0.153M | -0.001M | -0M | - |
| Operating Income | -6.455M | -4.392M | -3.623M | -3.826M | -4.101M |
| Other Operating Expenses | 6.455M | 4.392M | 3.623M | 3.826M | 4.101M |
| Interest Expense | 0M | 0.001M | 0.003M | 0M | 0M |
| Tax Provision | - | - | - | - | - |
| Interest Income | 1.937M | 0.158M | - | - | - |
| Net Interest Income | 1.937M | 0.157M | -0.003M | -0M | - |
| Income Tax Expense | -1.937M | -0.153M | 0.003M | 0M | -0.033M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 6.455M | 4.392M | 3.623M | 3.826M | 4.101M |
| Cost Of Revenue | - | - | - | - | - |
| Total Other Income Expense Net | 0.202M | 0.153M | 0.072M | -0M | 0.033M |
| Net Income From Continuing Ops | -4.316M | -4.239M | -3.551M | -3.827M | -4.067M |
| Net Income Applicable To Common Shares | - | -4.239M | -3.551M | -3.827M | -4.067M |
Balance Sheet
(Currency in USD)| Breakdown | 30-04-2023 | 30-04-2022 | 30-04-2021 | 30-04-2020 | 30-04-2019 |
|---|---|---|---|---|---|
| Total Assets | 73.277M | 90.624M | 7.404M | 6.167M | 5.782M |
| Intangible Assets | 3.549M | 3.549M | 3.549M | 3.549M | 3.549M |
| Other Current Assets | 0.108M | 0.094M | 0.073M | -1.429M | 0.138M |
| Total Liab | 0.587M | 0.704M | 0.725M | 1.078M | 0.743M |
| Total Stockholder Equity | 72.69M | 89.92M | 6.679M | 5.089M | 5.04M |
| Other Current Liab | 0.458M | 0.499M | 0.553M | 0.817M | 0.24M |
| Common Stock | 0.002M | 0.002M | 0M | 0.164M | 0.119M |
| Capital Stock | 0.002M | 0.002M | 0M | 0.164M | 0.119M |
| Retained Earnings | -115.959M | -111.649M | -107.409M | -103.858M | -100.031M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.008M | 0.007M | 0.007M | 0.007M |
| Cash | 68.04M | 85.401M | 2.202M | 0.895M | 0.515M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 0.587M | 0.704M | 0.725M | 1.031M | 0.743M |
| Current Deferred Revenue | - | - | - | - | - |
| Net Debt | -68.04M | -85.401M | -2.202M | -0.82M | -0.515M |
| Short Term Debt | - | - | - | 0.029M | - |
| Short Long Term Debt | - | - | - | 0.029M | - |
| Short Long Term Debt Total | - | - | - | 0.075M | - |
| Other Stockholder Equity | 188.67M | 201.582M | -0.02M | 108.805M | 104.952M |
| Property Plant Equipment | - | - | - | - | - |
| Total Current Assets | 68.148M | 85.495M | 2.275M | 1.038M | 0.653M |
| Long Term Investments | 1.572M | 1.572M | 1.572M | 1.572M | 1.572M |
| Short Term Investments | - | - | - | 1.572M | - |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | - | - | - | 0.046M | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 0.128M | 0.205M | 0.172M | 0.186M | 0.122M |
| Accumulated Other Comprehensive Income | -0.023M | -0.016M | -0.02M | -0.022M | -0.014M |
| Non Currrent Assets Other | 0.008M | 0.008M | 0.007M | 0.007M | 0.007M |
| Non Current Assets Total | 5.129M | 5.129M | 5.129M | 5.129M | 5.129M |
| Capital Lease Obligations | - | - | - | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 30-04-2023 | 30-04-2022 | 30-04-2021 | 30-04-2020 | 30-04-2019 |
|---|---|---|---|---|---|
| Investments | 0M | 0M | 0M | 0M | 0M |
| Total Cashflows From Investing Activities | - | - | - | - | - |
| Total Cash From Financing Activities | -13.56M | 87.311M | 4.637M | 2.726M | 2.343M |
| Net Income | -4.316M | -4.239M | -3.551M | -3.827M | -4.067M |
| Change In Cash | -17.361M | 83.199M | 1.307M | 0.38M | -0.545M |
| Begin Period Cash Flow | 85.401M | 2.202M | 0.895M | 0.515M | 1.06M |
| End Period Cash Flow | 68.04M | 85.401M | 2.202M | 0.895M | 0.515M |
| Total Cash From Operating Activities | -3.794M | -4.117M | -3.331M | -2.338M | -2.878M |
| Depreciation | - | - | - | - | - |
| Other Cashflows From Investing Activities | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | -13.561M | - | - | -0M | - |
| Other Cashflows From Financing Activities | 0.001M | 87.311M | - | 0.075M | - |
| Capital Expenditures | 0M | 0M | 0M | 0M | 0M |
| Change In Working Capital | -0.297M | 0.009M | -0.146M | 0.267M | 0.167M |
| Other Non Cash Items | 0.174M | 0.035M | -0.005M | 0.473M | 0.317M |
| Free Cash Flow | -3.794M | -4.117M | -3.331M | -2.338M | -2.878M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 116135 |
| 2. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 74919 |
| 3. | Fidelity Total Market Index | 2 years ago | 66102 |
| 4. | Fidelity Extended Market Index | 2 years ago | 62629 |
| 5. | Fidelity Nasdaq Composite Index | 2 years ago | 26211 |
| 6. | Fidelity Series Total Market Index | 2 years ago | 21092 |
| 7. | Spartan Total Market Index Pool E | 2 years ago | 19290 |
| 8. | iShares Micro-Cap ETF | 2 years ago | 18844 |
| 9. | NT Ext Equity Mkt Idx Fd - NL | 2 years ago | 14428 |
| 10. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 2 years ago | 11588 |
| 11. | Dimensional US Core Equity 2 ETF | 2 years ago | 11506 |
| 12. | Dimensional US Targeted Value ETF | 2 years ago | 8707 |
| 13. | Schwab Total Stock Market Index | 2 years ago | 5947 |
| 14. | Dimensional Global Core Equity USD Acc | 2 years ago | 5379 |
| 15. | Spartan Extended Market Index Pool E | 2 years ago | 4921 |
| 16. | DFA US Vector Equity I | 2 years ago | 4103 |
| 17. | Northern Trust Extended Eq Market Idx | 2 years ago | 4020 |
| 18. | NT Ext Equity Mkt Idx Fd - L | 2 years ago | 4020 |
| 19. | DFA US Core Equity 1 I | 2 years ago | 3571 |
| 20. | 1290 VT Micro Cap K | 2 years ago | 1618 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | K2 PRINCIPAL FUND LP | 2 years ago | 327503 |
| 2. | Geode Capital Management, LLC | 2 years ago | 215637 |
| 3. | Vanguard Group Inc | 2 years ago | 174602 |
| 4. | EQUITEC PROPRIETARY MARKETS, LLC | 2 years ago | 82727 |
| 5. | Sabby Management LLC | 2 years ago | 82373 |
| 6. | Renaissance Technologies Corp | 2 years ago | 38100 |
| 7. | BlackRock Inc | 2 years ago | 28769 |
| 8. | Dimensional Fund Advisors, Inc. | 2 years ago | 24563 |
| 9. | Susquehanna International Group, LLP | 2 years ago | 22028 |
| 10. | Northern Trust Corp | 2 years ago | 19283 |
| 11. | Bank of New York Mellon Corp | 2 years ago | 16598 |
| 12. | Acadian Asset Management LLC | 2 years ago | 3589 |
| 13. | Tower Research Capital LLC | 2 years ago | 1875 |
| 14. | Advisor Group Holdings, Inc. | 2 years ago | 1758 |
| 15. | CWM, LLC duplicate | 2 years ago | 954 |
| 16. | Aspire Private Capital, LLC | 2 years ago | 800 |
| 17. | Royal Bank of Canada | 2 years ago | 265 |
| 18. | Covestor Ltd | 2 years ago | 226 |
| 19. | Bank of America Corp | 2 years ago | 62 |
| 20. | Wells Fargo & Co | 2 years ago | 55 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...